1
|
Fahmy HM, Abd El-Daim TM, Mohamed HAAENE, Mahmoud EAAEQ, Abdallah EAS, Mahmoud Hassan FEZ, Maihop DI, Amin AEAE, Mustafa ABE, Hassan FMA, Mohamed DME, Shams-Eldin EMM. Multifunctional nanoparticles in stem cell therapy for cellular treating of kidney and liver diseases. Tissue Cell 2020; 65:101371. [PMID: 32746989 DOI: 10.1016/j.tice.2020.101371] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/24/2019] [Revised: 04/22/2020] [Accepted: 04/23/2020] [Indexed: 12/13/2022]
Abstract
The review gives an overview of the mechanisms of internalization and distribution of nanoparticles in stem cells this is achieved via providing analysis of the methods used in exploring the migration routes of stem cells, and their reciprocity. In addition, exploring microenvironment target in the body, and tracking the fate of exogenously transplanted stem cells by using innovative and non-invasive techniques will also be discussed. Such techniques like magnetic resonance imaging (MRI), multimodality tracking, optical imaging, and nuclear medicine imaging, which were designed to follow up stem cell migration. This review will explain the various distinctive strategies to enhance homing of labeled stem cells with nanoparticles into damaged hepatic and renal tissues, this purpose was obtained by inducing a specific gene into stem cells, various chemokines, and applying an external magnetic field. Also, this work illustrates how to improve nanoparticles uptake by using transfection agents or covalently binding an exogenous protein (i.e., Human immunodeficiency virus-Tat protein) or conjugating a receptor-specific monoclonal antibody or make modifications to iron coat. It contains stem cell labeling methods such as extracellular labeling and internalization approaches. Ultimately, our review indicates trails of researchers in nanoparticles utilization in stem cell therapy in both kidney and liver diseases.
Collapse
|
2
|
Silachev DN, Kondakov AK, Znamenskii IA, Kurashvili YB, Abolenskaya AV, Antipkin NR, Danilina TI, Manskikh VN, Gulyaev MV, Pirogov YA, Plotnikov EY, Zorov DB, Sukhikh GT. The Use of Technetium-99m for Intravital Tracing of Transplanted Multipotent Stromal Cells. Bull Exp Biol Med 2016; 162:153-159. [PMID: 27882463 DOI: 10.1007/s10517-016-3565-1] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2016] [Indexed: 11/29/2022]
Abstract
We studied the possibility of in vivo tracing of multipotent mesenchymal stromal cells labeled with a radiophermaceutic preparation based on metastable isotope Technetium-99m and injected to rats with modeled traumatic brain injury. Accumulation of labeled cells occurred primarily in the liver and lungs. The cells distribution in internal organs greatly varied depending on the administration route. Cell injection into the carotid artery led to their significant accumulation in the damaged brain hemisphere, while intravenous injection was followed by diffuse cell distribution in all brain structures. Scintigraphy data were confirmed by magnetic resonance imaging and histological staining of cells. Visualization of stem cells labeled with Technetium-99m-based preparation by scintigraphy is an objective and highly informative method allowing real-time in vivo cell tracing in the body.
Collapse
Affiliation(s)
- D N Silachev
- V. I. Kulakov Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of the Russian Federation, Moscow, Russia.,A. N. Belozersky Institute of Physico-Chemical Biology, M. V. Lomonosov Moscow State University, Moscow, Russia
| | - A K Kondakov
- N. I. Pirogov National Russian Research Medical University, Ministry of Health of the Russian Federation, Moscow, Russia.,Hospital for Incurable Patients - Research Medical Rehabilitation Center, Moscow, Russia
| | - I A Znamenskii
- N. I. Pirogov National Russian Research Medical University, Ministry of Health of the Russian Federation, Moscow, Russia.,Hospital for Incurable Patients - Research Medical Rehabilitation Center, Moscow, Russia
| | - Yu B Kurashvili
- National Research Nuclear University MEPhI, Moscow, Russia.,P. A. Hertsen Moscow Oncology Research Institute, Moscow, Russia
| | - A V Abolenskaya
- P. A. Hertsen Moscow Oncology Research Institute, Moscow, Russia
| | - N R Antipkin
- P. A. Hertsen Moscow Oncology Research Institute, Moscow, Russia
| | - T I Danilina
- A. N. Belozersky Institute of Physico-Chemical Biology, M. V. Lomonosov Moscow State University, Moscow, Russia
| | - V N Manskikh
- A. N. Belozersky Institute of Physico-Chemical Biology, M. V. Lomonosov Moscow State University, Moscow, Russia
| | - M V Gulyaev
- Laboratory of Magnetic Tomography and Spectroscopy, Faculty of Fundamental Medicine, M. V. Lomonosov Moscow State University, Moscow, Russia
| | - Yu A Pirogov
- Laboratory of Magnetic Tomography and Spectroscopy, Faculty of Fundamental Medicine, M. V. Lomonosov Moscow State University, Moscow, Russia
| | - E Yu Plotnikov
- V. I. Kulakov Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of the Russian Federation, Moscow, Russia.,A. N. Belozersky Institute of Physico-Chemical Biology, M. V. Lomonosov Moscow State University, Moscow, Russia
| | - D B Zorov
- V. I. Kulakov Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of the Russian Federation, Moscow, Russia. .,A. N. Belozersky Institute of Physico-Chemical Biology, M. V. Lomonosov Moscow State University, Moscow, Russia.
| | - G T Sukhikh
- V. I. Kulakov Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of the Russian Federation, Moscow, Russia
| |
Collapse
|
3
|
Tuganbekova S, Gaipov A, Turebekov Z, Saparbayev S, Shaimardanova G, Popova N, Taubaldiyeva Z, Serebrennikova D, Trimova R. Fetal Renal Stem Cell Transplant in Nephrotic and Nonnephrotic Glomerulonephritis with Stage 2-4 Chronic Kidney Disease: Potential Effect on Proteinuria and Glomerular Filtration Rate. EXP CLIN TRANSPLANT 2015; 13 Suppl 3:156-9. [PMID: 26640940 DOI: 10.6002/ect.tdtd2015.p88] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
OBJECTIVES Proteinuria is a major cause of glomerulosclerosis progression in glomerular diseases, and the development of end-stage renal disease is more rapid in nephrotic patients than in nonnephrotic ones. The renal parenchyma is less regenerable because it is a tissue consisting of renal cells. Thus, stem cells obtained from fetal kidney tissue might be effective for reducing proteinuria and delaying glomerulosclerosis in these patients. MATERIALS AND METHODS This report presents preliminary data from a prospective cohort study that included 17 patients with chronic glomerulonephritis in stage 2 to 4 chronic kidney disease who completed 3 visits during 1 year of follow-up. Fetal renal stem cells (multiple cells in suspension) were injected into the patient every 6 months. Patients were divided into 2 groups according to their nephrotic status, and 24-hour maximal proteinuria was recorded for at least 6 months (first group with proteinuria < 3.5 g/24 h, and second group with proteinuria > 3.5 g/24 h). RESULTS During follow-up, group 1 was observed to have stable hemoglobin and total protein levels but significantly decreased albumin levels and glomerular filtration rates. In group 2, total protein with serum albumin significantly increased, and proteinuria and glomerular filtration rates significantly decreased. There was no significant difference in glomerular filtration rate decline between groups. CONCLUSIONS Treatment with fetal renal stem cells significantly decreased proteinuria in nephrotic patients. However, this outcome also might have resulted from a reduction in glomerular filtration rate. Further studies with a larger number of patients and a control group would help to achieve better results that measure the efficacy of this treatment.
Collapse
Affiliation(s)
- Saltanat Tuganbekova
- From the Department of Internal Medicine, National Scientific Medical Research Center, Astana, Kazakhstan
| | | | | | | | | | | | | | | | | |
Collapse
|